Advertisement

Comparison of Late (3-Year) Registry Data Outcomes Using Bare Metal Versus Drug-Eluting Stents for Treating ST-Segment Elevation Acute Myocardial Infarctions

      Clinical trial data have supported the safety and efficacy of drug-eluting stents (DES) in the treatment of patients with ST-segment elevation myocardial infarctions (STEMIs), but contemporary “real-world” registry data regarding the late safety profiles of DES are limited. This prospective registry-based study included 1,569 consecutive unselected patients with STEMIs who underwent emergency primary percutaneous coronary intervention from January 2001 to December 2009. Of the study cohort, 200 patients (12.7%) received DES, while 1,369 patients (87.3%) underwent bare-metal stent (BMS) placement. The primary end points of the study were all-cause mortality and target vessel revascularization at 1, 2, and 3 years. Survival status was assessed by municipal civil registries. Repeat revascularization procedures were prospectively collected in the hospital database. All-cause mortality was significantly lower in the DES group at 3 years (4.2% vs 13.5%, p = 0.007) compared to BMS-treated patients, but DES use was not an independent predictor of all-cause mortality (adjusted odds ratio 0.5, 95% confidence interval 0.2 to 1.2, p = 0.10). Target vessel revascularization was significantly lower in the DES group compared to the BMS group at 3 years (10.5% vs 21%, p = 0.001). DES use was an independent predictor of reduced target vessel revascularization (adjusted odds ratio 0.44, 95% confidence interval 0.25 to 0.77, p = 0.004). Late definite stent thrombosis occurring after 1 year occurred in 4 (2.5%) patients in the DES group compared to 6 (0.7%) in the BMS group (p = 0.05). DES use was an independent predictor of late stent thrombosis (adjusted odds ratio 8.6, 95% confidence interval 1.9 to 38, p = 0.004). In conclusion, this contemporary registry-based study of patients who underwent primary percutaneous coronary intervention for STEMI demonstrated improved revascularization rates without increased 3-year hazard of adverse clinical outcomes in DES-treated patients.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Brodie B.R.
        • Stuckey T.
        • Downey W.
        • Humphrey A.
        • Nussbaum M.
        • Laurent S.
        • Bradshaw B.
        • Metzger C.
        • Hermiller J.
        • Krainin F.
        • Juks S.
        • Cheek B.
        • Duffy P.
        • Simonton C.A.
        • Strategic Transcatheter Evaluation of New Therapies (STENT) Group
        Outcomes with drug-eluting stents versus bare metal stents in acute ST-elevation myocardial infarction: results from the Strategic Transcatheter Evaluation of New Therapies (STENT) group.
        Catheter Cardiovasc Interv. 2008; 72: 893-900
        • Hannan E.L.
        • Racz M.
        • Walford G.
        • Holmes D.R.
        • Jones R.H.
        • Sharma S.
        • Katz S.
        • King III, S.B.
        Drug-eluting versus bare-metal stents in the treatment of patients with ST-segment elevation myocardial infarction.
        JACC Cardiovasc Interv. 2008; 1: 129-135
        • Kaltoft A.
        • Jensen L.O.
        • Maeng M.
        • Tilsted H.H.
        • Thayssen P.
        • Bottcher M.
        • Lassen J.F.
        • Krusell L.R.
        • Rasmussen K.
        • Hansen K.N.
        • Pedersen L.
        • Johnsen S.P.
        • Sorensen H.T.
        • Thuesen L.
        2-Year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry).
        J Am Coll Cardiol. 2009; 53: 658-664
        • Lemos P.A.
        • Saia F.
        • Hofma S.H.
        • Daemen J.
        • Ong A.T.
        • Arampatzis C.A.
        • Hoye A.
        • McFadden E.
        • Sianos G.
        • Smits P.C.
        • van der Giessen W.J.
        • de Feyter P.
        • van Domburg R.T.
        • Serruys P.W.
        Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction.
        J Am Coll Cardiol. 2004; 43: 704-708
        • Mauri L.
        • Silbaugh T.S.
        • Garg P.
        • Wolf R.E.
        • Zelevinsky K.
        • Lovett A.
        • Varma M.R.
        • Zhou Z.
        • Normand S.L.
        Drug-eluting or bare-metal stents for acute myocardial infarction.
        N Engl J Med. 2008; 359: 1330-1342
        • Steg P.G.
        • Fox K.A.
        • Eagle K.A.
        • Furman M.
        • Van de Werf F.
        • Montalescot G.
        • Goodman S.G.
        • Avezum A.
        • Huang W.
        • Gore J.M.
        Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events.
        Eur Heart J. 2009; 30: 321-329
        • Pierre-Louis B.
        • Aronow W.S.
        • Palaniswamy C.
        • Singh T.
        • Ahn C.
        • Asija A.
        • Weiss M.B.
        • Kalapatapu K.
        • Pucillo A.L.
        • Monsen C.E.
        Major adverse cardiac events at follow-up after bare-metal stenting versus drug-eluting stenting in ST-elevated myocardial infarction.
        Am J Cardiol. 2009; 103: 1672-1674
        • Campo G.
        • Saia F.
        • Percoco G.
        • Manari A.
        • Santarelli A.
        • Vignali L.
        • Varani E.
        • Benassi A.
        • Sangiorgio P.
        • Tarantino F.
        • Magnavacchi P.
        • De Palma R.
        • Guastaroba P.
        • Marzocchi A.
        Long-term outcome after drug eluting stenting in patients with ST-segment elevation myocardial infarction: data from the REAL registry.
        Int J Cardiol. 2010; 140: 154-160
        • George J.C.
        • Dangas G.D.
        2009 focused updates to guidelines in ST-elevation myocardial infarction and percutaneous coronary intervention: application to interventional cardiology.
        JACC Cardiovasc Interv. 2010; 3: 256-258
        • Stuart E.A.
        Matching methods for causal inference: a review and a look forward.
        Stat Sci. 2010; 25: 1-21
        • Rosenbam P.R.
        • Rubin D.B.
        The central role of the propensity score in observational studies for causal effects.
        Biometrika. 1985; 70: 41-55
        • Little R.J.
        • Rubin D.B.
        Causal effects in clinical and epidemiological studies via potential outcomes: concepts and analytical approaches.
        Annu Rev Public Health. 2000; 21: 121-145
        • Halkin A.
        • Singh M.
        • Nikolsky E.
        • Grines C.L.
        • Tcheng J.E.
        • Garcia E.
        • Cox D.A.
        • Turco M.
        • Stuckey T.D.
        • Na Y.
        • Lanksy A.J.
        • Gersh B.J.
        • O'Neill W.W.
        • Mehran R.
        • Stone G.W.
        Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score.
        J Am Coll Cardiol. 2005; 45: 1397-1405
        • Vink M.A.
        • Dirksen M.T.
        • Suttorp M.J.
        • Tijssen J.G.
        • van Etten J.
        • Patterson M.S.
        • Slagboom T.
        • Kiemeneij F.
        • Laarman G.J.
        5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial.
        JACC Cardiovasc Intverv. 2011; 4: 24-29
        • Dibra A.
        • Tiroch K.
        • Schulz S.
        • Kelbaek H.
        • Spaulding C.
        • Laarman G.J.
        • Valgimigli M.
        • Di Lorenzo E.
        • Kaiser C.
        • Tierala I.
        • Campo G.
        • Thuesen L.
        • Vink M.A.
        • Schalij M.J.
        • Violini R.
        • Schomig A.
        • Mehilli J.
        • Kastrati A.
        Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials.
        Clin Res Cardiol. 2010; 99: 345-357
        • Stone G.W.
        • Witzenbichler B.
        • Guagliumi G.
        • Peruga J.Z.
        • Brodie B.R.
        • Dudek D.
        • Kornowski R.
        • Hartmann F.
        • Gersh B.J.
        • Pocock S.J.
        • Dangas G.
        • Wong S.C.
        • Fahy M.
        • Parise H.
        • Mehran R.
        • HORIZONS-AMI Trial Investigators
        Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial.
        Lancet. 2011; 377: 2193-2204